The use of an anti-PD-1 antibody or anti-PD-L1 antibody can effectively inhibit immune dysfunction caused by the PD-1/PD-L1 axis, leading to the alleviation of T-cell suppression and the augmentation of the anti-tumor response. Here, PDCD1 is linked to neoplasm.